Scarica l'app Stockscreener
19.45
0.26%
-0.05
Dopo l'orario di chiusura:
19.69
0.24
+1.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$19.50
Aprire:
$19.38
Volume 24 ore:
3.36M
Relative Volume:
2.47
Capitalizzazione di mercato:
$2.42B
Reddito:
$181.74M
Utile/perdita netta:
$-296.81M
Rapporto P/E:
-11.37
EPS:
-1.71
Flusso di cassa netto:
$-402.70M
1 W Prestazione:
-10.98%
1M Prestazione:
+3.96%
6M Prestazione:
-18.24%
1 anno Prestazione:
-30.11%
Intervallo 1D:
$19.18
$20.21
Intervallo di 1 settimana:
$19.18
$22.47
Portata 52W:
$17.05
$39.83
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Nome
Arrowhead Pharmaceuticals Inc
Settore
Industria
Telefono
626-696-4702
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Confronta ARWR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
19.45 | 2.42B | 181.74M | -296.81M | -402.70M | -2.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-05 | Iniziato | Goldman | Neutral |
| 2023-12-04 | Iniziato | BofA Securities | Buy |
| 2023-09-19 | Iniziato | Citigroup | Neutral |
| 2023-07-21 | Iniziato | TD Cowen | Outperform |
| 2023-05-12 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-12 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Ripresa | Goldman | Buy |
| 2021-08-06 | Reiterato | Chardan Capital Markets | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-19 | Iniziato | Citigroup | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Iniziato | Goldman | Neutral |
| 2020-01-21 | Iniziato | SVB Leerink | Underperform |
| 2019-12-13 | Iniziato | Oppenheimer | Perform |
| 2019-11-29 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-27 | Reiterato | B. Riley FBR | Buy |
| 2019-11-25 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Reiterato | Chardan Capital Markets | Buy |
| 2019-10-03 | Iniziato | Robert W. Baird | Outperform |
| 2018-09-07 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-08-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Insider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells 26,712 Shares of Stock - MarketBeat
Arrowhead Pharmaceuticals CEO sells $567,485 in stock By Investing.com - Investing.com UK
Ionis To Get Head Start On Arrowhead With Tryngzola Launch - Citeline News & Insights
HC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Raised to Sell at StockNews.com - MarketBeat
Arrowhead Pharma Approves Major Employee Stock Grants, Expands Workforce with 20 New Hires - StockTitan
Arrowhead Pharmaceuticals director sells shares totaling $121,555 By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director William D. Waddill Sells 3,748 Shares - MarketBeat
Arrowhead Pharmaceuticals director sells $164,665 in stock - Investing.com India
Arrowhead Pharmaceuticals director sells $164,665 in stock By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals director sells shares totaling $121,555 - Investing.com
Arrowhead Pharmaceuticals director Victoria Vakiener sells $197,058 in stock - Investing.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $42.70 Average PT from Brokerages - MarketBeat
Research Analysts Set Expectations for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Short Interest Update - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by State Street Corp - MarketBeat
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock faces pivotal year - Investing.com
Jane Street Group LLC Reduces Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
(ARWR) Technical Pivots with Risk Controls - Stock Traders Daily
Chardan Capital Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases - BioSpace
Hypercholesterolemia Pipeline 2024: Clinical Trials - openPR
Arrowhead Pharma Shares See Big Price Jump - Los Angeles Business Journal
Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) have lost 66%, as stock drops 9.3% this past week - Yahoo Finance
What is HC Wainwright's Estimate for ARWR Q1 Earnings? - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by Verition Fund Management LLC - MarketBeat
Research Analysts Issue Forecasts for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Fmr LLC - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 135,904 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Erste Asset Management GmbH Acquires New Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - The Bakersfield Californian
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences - BioSpace
(ARWR) Trading Advice - Stock Traders Daily
Arrowhead, Sarepta Stocks Rise Despite Price-Target Cuts Post $1B Licensing Deal: Retail Buzz Strong - MSN
Intech Investment Management LLC Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Fisher Asset Management LLC Grows Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target Cut to $24.00 by Analysts at Sanford C. Bernstein - MarketBeat
Arrowhead price target lowered to $24 from $27 at Bernstein - Yahoo Finance
Deal Watch: Sarepta Targets RNAi In Broad Collaboration With Arrowhead - News & Insights
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2024 Earnings Call Transcript - Insider Monkey
Antisense & RNAi Therapeutics Global Market Report 2024 To 2033 | - openPR
Arrowhead Pharmaceuticals Faces Distribution Risks with Vanscoy Reliance - Yahoo Finance
Arrowhead Pharmaceuticals’ Lincense Collaboration Agreement with Sarepta Therapeutics - Global Legal Chronicle
Arrowhead: The Sarepta Partnership Validates RNAi Platform And Reduces Risk (NASDAQ:ARWR) - Seeking Alpha
Insiders Sold US$1.6m Of Arrowhead Pharmaceuticals Stock Possibly Sending Warning Sign - Simply Wall St
Sarepta Therapeutics licenses programs from Arrowhead Pharmaceuticals - BioWorld Online
Arrowhead Stock Rockets 16% After Major Licensing Deal - GuruFocus.com
Earnings call: Arrowhead Pharmaceuticals reports transformative year By Investing.com - Investing.com South Africa
Earnings call: Arrowhead Pharmaceuticals reports transformative year - Investing.com India
Chardan Capital Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Sarepta rebuilds drug pipeline with Arrowhead deal - Yahoo Finance
Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arrowhead Pharmaceuticals Inc Azioni (ARWR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Waddill William D. | Director |
Dec 17 '24 |
Sale |
22.04 |
3,747 |
82,584 |
40,378 |
| Waddill William D. | Director |
Dec 16 '24 |
Sale |
21.90 |
3,748 |
82,081 |
44,125 |
| GIVEN DOUGLAS B | Director |
Dec 16 '24 |
Sale |
21.90 |
5,000 |
109,500 |
124,714 |
| GIVEN DOUGLAS B | Director |
Dec 17 '24 |
Sale |
22.04 |
547 |
12,056 |
124,167 |
| Vakiener Victoria | Director |
Dec 16 '24 |
Sale |
21.91 |
8,994 |
197,059 |
21,211 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):